



Docket No. 5135 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO/SB/08A) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

## This Information Disclosure Statement:

(a) [ ] accompanies a new patent application submitted herewith.

(b) [ ] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.

(c) [X] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.

(d) [ ] as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.

(e) [ ] is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

(f) [ ] is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

[ ] Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

[ ] No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the non-patent literature items listed on PTO/SB/08A are supplied herewith in accordance with 37 CFR §1.98(a)(2).

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: 11-22-04

  
\_\_\_\_\_  
Andrew K. Finn, Reg. No. 54,097  
Agent for Applicants

**Correspondence Address**

Customer Number 22896  
APPLERA CORPORATION  
Applied Biosystems Group  
850 Lincoln Centre Drive  
Foster City, CA 94404  
(650) 638-6245 (Phone)  
(650) 638-6677 (Fax)

Please type a plus sign (+) inside this box. → +

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	10/723,388		
		Filing Date	November 25, 2003		
		First Named Inventor	Dimsoski et al.		
		Group Art Unit	1632		
		Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket No.	5135 US

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code <sup>2</sup>				
01	RE37,984	E	JACKLE et al.	02/11/2003			
02	6,479,235	B1	SCHUMM et al.	11/12/2002			
03	6,312,902	B1	SHULTZ et al.	11/06/2001			
04	6,221,598	B1	SCHUMM et al.	04/24/2001			
05	5,888,819		GOELET et al.	03/30/1999			
06	5,874,217		HALVERSON et al.	02/23/1999			
07	5,843,660		SCHUMM et al.	12/01/1998			
08	5,783,406		SCHUMM et al.	07/21/1998			
09	5,766,847		JACKLE et al.	06/16/1998			
10	5,674,686		SCHUMM et al.	10/07/1997			
11	5,599,666		SCHUMM et al.	02/04/1997			
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	12	P. ROSS et al., "Analysis of Short Tandem Repeat Polymorphisms in Human DNA by Matrix-assisted Laser Desorption/Ionization Mass Spectrometry" Anal. Chem., Vol. 69, (1997), pp. 3966-3972				
	13	G. TULLY et al., "Forensic Analysis of Mitochondrial DNA: Application of Multiplex Solid-phase - Fluorescent Minisequencing to High Throughput Analysis" Genetic Identity Conference Proceedings, 2 <sup>nd</sup> European Symposium on Human Identification 1998, pp. 92-96				
	14	M. WOJCIECHOWSKI et al. "Multichannel Electrochemical Detection System for Quantitative Monitoring of PCR Amplification" Clinical Chemistry, Vol. 45, No. 9, (1999), pp. 1690-1693				
	15	J. MORLEY et al., "Validation of Mitochondrial DNA Minisequencing for Forensic Casework" Int. J. Legal Med., Vol. 112, No. 4, (1999), pp. 241-248				

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 74810\_1

Please type a plus sign (+) inside this box. → Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/723, 388
				Filing Date	November 25, 2003
				First Named Inventor	Dimsoski et al.
				Group Art Unit	1632
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket No.	5135 US

OTHER ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	16	G. TULLY et al., "Rapid Detection of Mitochondrial Sequence Polymorphisms Using Multiplex Solid-phase Fluorescent Minisequencing" Genomics, Vol. 34, No. 1, May 1996, pp. 107-113			
	17	J. ROSS et al., "Multiplex PCR Amplification of Eight STR Loci in Austrian and Croatian Caucasian Populations" Int. J. Legal Med., Vol. 115, No. 1, (2001), pp. 57-60			
	18	J. BUTLER et al., "The Development of Reduced Size STR Amplicons as Tools for Analysis of Degraded DNA" J. Forensic Sci., Vol. 48, No. 5, September 2003, pp. 1054-1064			
	19	P. GRUBWIESER et al., "Systematic Study on STR Profiling on Blood and Saliva Traces After Visualization of Fingerprint Marks" J. Forensic Sci., Vol. 48, No. 4, July 2003, pp. 733-741			
	20	A. HELLMANN et al., "STR Typing of Human Telogen Hairs-A New Approach" Int. J. Legal Med., Vol. 114, No. 4, (2001), pp. 269-273			
	21	C. FREGEAU et al., "DNA Typing with Fluorescently Tagged Short Tandem Repeats: A Sensitive and Accurate Approach to Human Identification" Biotechniques, Vol. 15, No. 1, July 1993, pp. 100-119			
	22	D. TAUTZ et al., "Cryptic Simplicity in DNA is a Major Source of Genetic Variation" Nature, vol. 322, No. 6080, August 14-20, 1986, pp. 652-656			
	23	"PCR Product Detection" product information produced from Thermo Electron Corporation company website on July 17, 2003, <a href="http://www.thermo.com">www.thermo.com</a> , 3 pages			
	24	"Automated Magnetic Purification of Single-stranded Templates for Pyrosequencing™ Using Magnatrix™ 1200 and Regenerable Magnetic Streptavidin Beads" product information produced from Magnetic Biosolutions AB company website, <a href="http://www.magbio.com">www.magbio.com</a> , 2 pages			
	25	"Rapid PCR Product Detection Test Kit - Rapid PCR-direct Reagent Kit" product information produced from Alderon Biosciences Incorporated company website on July 17, 2003, <a href="http://www.alderonbiosciences.com">www.alderonbiosciences.com</a> , 5 pages			
	26	"Nucleic Acid Diagnostics" product information produced from Hydros, Inc. company website on July 18, 2003, <a href="http://www.hydros.cc">www.hydros.cc</a> , 2 pages			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 74810\_1